Sunbird Bio focused on advancing diagnostics for neurological disorders. The company developed technologies to improve the detection and understanding of these complex conditions. Their work aimed to support patient care through enhanced diagnostic tools.
Funding
Funding not disclosed
Founders
Product
Problem
Diagnosing and monitoring neurodegenerative diseases like Alzheimer's and Parkinson's is challenging due to the limitations of current methods, including expensive and inaccessible PET imaging, invasive cerebrospinal fluid tests, and subjective cognitive assessments. These limitations hinder early detection, timely treatment, and effective monitoring of disease progression.
Solution
Sunbird Bio is developing the APEX technology platform, a blood-based diagnostic test designed to directly detect and differentiate specific proteins associated with Alzheimer's and Parkinson's diseases. This non-invasive approach offers the potential for earlier and more accurate diagnosis, enabling timely treatment decisions and improved patient outcomes. The APEX test aims to provide researchers and clinicians with actionable information currently unavailable or inaccessible through existing diagnostics, with data showing over 90% correlation to gold-standard PET imaging in Alzheimer's patients. By overcoming the challenges of traditional diagnostic methods, Sunbird Bio seeks to improve standards of care and accelerate drug development in the field of neurological disorders.
Target Audience
The primary audience includes researchers and clinicians specializing in neurological disorders, particularly Alzheimer's and Parkinson's disease, who require more sensitive, reliable, and non-invasive diagnostic tools.
Features
- Blood-based diagnostic test for Alzheimer's and Parkinson's diseases
- APEX technology platform directly detects and differentiates disease-specific proteins
- Non-invasive alternative to PET imaging and cerebrospinal fluid tests
- High correlation (over 90%) with gold-standard PET imaging in Alzheimer's patients